| Segment Reporting [Text Block] |
Note 11. Segment Information
Segment information is prepared on the same basis our chief operating decision maker ("CODM"), our CEO, uses to assess segment performance, allocate resources, evaluate financial results, and make key operating decisions. Our four reportable segments are organized primarily by the nature of the goods and services they sell. Our CODM regularly reviews segment-level U.S. GAAP revenue and gross profit relative to forecasted and prior period amounts, as well as non-GAAP adjusted operating expense compared to budgeted amounts. Our CODM also regularly reviews non-GAAP organic revenue growth to support strategic planning and resource deployment.
The following tables set forth our segment information:
| Three months ended June 30, 2026 |
|
Sterilization and Disinfection Control |
|
|
Biopharmaceutical Development |
|
|
Calibration Solutions |
|
|
Clinical Genomics |
|
|
Total |
|
| Revenue (a): |
|
$ |
24,505 |
|
|
$ |
12,059 |
|
|
$ |
13,285 |
|
|
$ |
10,289 |
|
|
$ |
60,138 |
|
| Less |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation in cost of revenue |
|
|
437 |
|
|
|
78 |
|
|
|
111 |
|
|
|
119 |
|
|
|
745 |
|
| Amortization in cost of revenue |
|
|
121 |
|
|
|
379 |
|
|
|
- |
|
|
|
191 |
|
|
|
691 |
|
| Other cost of revenue (b) |
|
|
6,788 |
|
|
|
4,020 |
|
|
|
5,143 |
|
|
|
3,739 |
|
|
|
19,690 |
|
| Total segment cost of revenue |
|
|
7,346 |
|
|
|
4,477 |
|
|
|
5,254 |
|
|
|
4,049 |
|
|
|
21,126 |
|
| Gross Profit (c) |
|
$ |
17,159 |
|
|
$ |
7,582 |
|
|
$ |
8,031 |
|
|
$ |
6,240 |
|
|
$ |
39,012 |
|
| Reconciling items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
31,981 |
|
| Operating income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,031 |
|
| Non-operating expense, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,678 |
|
| Earnings before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
4,353 |
|
| Three months ended June 30, 2025 |
|
Sterilization and Disinfection Control |
|
|
Biopharmaceutical Development |
|
|
Calibration Solutions |
|
|
Clinical Genomics |
|
|
Total |
|
| Revenue (a): |
|
$ |
25,410 |
|
|
$ |
11,486 |
|
|
$ |
12,350 |
|
|
$ |
10,297 |
|
|
$ |
59,543 |
|
| Less |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation in cost of revenue |
|
|
450 |
|
|
|
89 |
|
|
|
105 |
|
|
|
166 |
|
|
|
810 |
|
| Amortization in cost of revenue |
|
|
139 |
|
|
|
372 |
|
|
|
- |
|
|
|
191 |
|
|
|
702 |
|
| Other cost of revenue (b) |
|
|
6,655 |
|
|
|
4,719 |
|
|
|
5,203 |
|
|
|
4,515 |
|
|
|
21,092 |
|
| Total segment cost of revenue |
|
|
7,244 |
|
|
|
5,180 |
|
|
|
5,308 |
|
|
|
4,872 |
|
|
|
22,604 |
|
| Gross Profit (c) |
|
$ |
18,166 |
|
|
$ |
6,306 |
|
|
$ |
7,042 |
|
|
$ |
5,425 |
|
|
$ |
36,939 |
|
| Reconciling items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
33,875 |
|
| Operating income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,064 |
|
| Non-operating expense, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,948 |
) |
| Earnings before income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
7,012 |
|
| |
(a) |
Intersegment revenue are eliminated to arrive at consolidated totals. Revenue as presented are consistent with U.S. GAAP measurement principles and our CODM's review of segment information. |
| |
(b) |
Other segment cost of revenue for each reportable segment includes product costs, personnel costs (including stock-based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation and amortization. |
| |
(c) |
Gross profit as presented is consistent with U.S. GAAP measurement principles and our CODM's review of segment information. |
The following table sets forth inventories by reportable segment. Our CODM is not provided with and does not regularly review any other segment asset information.
| |
|
June 30, |
|
|
March 31, |
|
| |
|
2026 |
|
|
2026 |
|
| Sterilization and Disinfection Control |
|
$ |
5,516 |
|
|
$ |
5,943 |
|
| Biopharmaceutical Development |
|
|
6,528 |
|
|
|
6,512 |
|
| Calibration Solutions |
|
|
5,928 |
|
|
|
5,603 |
|
| Clinical Genomics |
|
|
9,257 |
|
|
|
8,315 |
|
| Total inventories |
|
$ |
27,229 |
|
|
$ |
26,373 |
|
|